Ocular melanoma

This trial tests a treatment called Melphalan/HDS for people whose eye melanoma has spread to the liver. The approach delivers high-dose melphalan, a chemotherapy drug, straight into the liver through a device system while limiting exposure to the rest of the body. Researchers wa…

This phase 3 trial tested whether a yeast-derived immune stimulant (GM-CSF) and a peptide vaccine, alone or together, could prevent melanoma from returning after surgery. 815 patients with no visible cancer after complete surgical removal of advanced melanoma were randomly assign…

This phase 2 trial tested the drug darovasertib in 15 people with high-risk uveal melanoma (a rare eye cancer) who were scheduled for eye removal surgery. Participants took the drug for up to 4 weeks before surgery, and some continued for 6 months afterward. The main goals were t…

This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infus…

This early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…

This study looked at the DNA changes (mutations) in eye cancers called ocular melanoma. Researchers analyzed tumor samples from 58 patients to understand how these cancers develop and spread. The goal was to identify key mutations that could lead to better treatments in the futur…